Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force

  • Mary SanoEmail author
  • M. Soto
  • M. Carrillo
  • J. Cummings
  • S. Hendrix
  • J. Mintzer
  • A. Porsteinsson
  • P. Rosenberg
  • L. Schneider
  • J. Touchon
  • P. Aisen
  • B. Vellas
  • C. Lyketsos
  • EU/US/CTAD Task Force members
CTAD Task Force Paper


For the second time in the past 3 years, the EU-US CTAD Task Force addressed challenges related to designing clinical trials for agitation in dementia, which is one of the most disruptive aspects of the condition for both patients and caregivers. Six recommendations emerged from the Task Force meeting: 1 – Operationalizing agitation criteria established by the IPA; 2 – Combining clinician- and caregiver-derived outcomes as primary outcome measures; 3 – Using global ratings to define clinically meaningful effects and power studies; 4 – Improving the accuracy of caregiver reports by better training and education of caregivers; 5 – Employing emerging technologies to collect near real-time behavioral data; and 6 – Utilizing innovative trial designs and increasing the use of biomarkers to maximize the productivity of clinical trials for neuropsychiatric symptoms.

Key words

Neuropsychiatric symptoms agitation dementia Alzheimer’s disease clinical trials NPS outcome measures 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gonzalez-Salvador MT, Arango C, Lyketsos CG, Barba AC. The stress and psychological morbidity of the Alzheimer patient caregiver. Int J Geriatr Psychiatry. 1999;14(9):701–10. PubMed PMID: 10479740.CrossRefPubMedGoogle Scholar
  2. 2.
    Peters ME, Schwartz S, Han D, Rabins PV, Steinberg M, Tschanz JT, et al. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry. 2015;172(5):460–5. doi: 10.1176/appi. ajp.2014.14040480. PubMed PMID: 25585033; PubMed Central PMCID: PMCPMC4416978.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Okura T, Plassman BL, Steffens DC, Llewellyn DJ, Potter GG, Langa KM. Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study. J Am Geriatr Soc. 2011;59(3):473–81. doi: 10.1111/j.1532-5415.2011.03314.x. PubMed PMID: 21391937; PubMed Central PMCID: PMCPMC3088883.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Murman DL, Chen Q, Powell MC, Kuo SB, Bradley CJ, Colenda CC. The incremental direct costs associated with behavioral symptoms in AD. Neurology. 2002;59(11):1721–9. PubMed PMID: 12473759.CrossRefPubMedGoogle Scholar
  5. 5.
    Costa N, Wubker A, De Mauleon A, Zwakhalen SMG, Challis D, Leino-Kilpi H, et al. Costs of Care of Agitation Associated With Dementia in 8 European Countries: Results From the RightTimePlaceCare Study. J Am Med Dir Assoc. 2018;19(1):95 e1–e10. doi: 10.1016/j.jamda.2017.10.013. PubMed PMID: 29275939.CrossRefGoogle Scholar
  6. 6.
    Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23(2):170–7. doi: 10.1002/gps.1858. PubMed PMID: 17607801; PubMed Central PMCID: PMCPMC2932652.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Craig D, Mirakhur A, Hart DJ, McIlroy SP, Passmore AP. A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer’s disease. Am J Geriatr Psychiatry. 2005;13(6):460–8. doi: 10.1176/appi.ajgp.13.6.460. PubMed PMID: 15956265.CrossRefPubMedGoogle Scholar
  8. 8.
    Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288(12):1475–83. PubMed PMID: 12243634.CrossRefPubMedGoogle Scholar
  9. 9.
    Cummings J, Mintzer J, Brodaty H, Sano M, Banerjee S, Devanand DP, et al. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. Int Psychogeriatr. 2015;27(1):7–17. doi: 10.1017/S1041610214001963. PubMed PMID: 25311499; PubMed Central PMCID: PMCPMC4301197.CrossRefPubMedGoogle Scholar
  10. 10.
    Soto M, Abushakra S, Cummings J, Siffert J, Robert P, Vellas B, et al. Progress in Treatment Development for Neuropsychiatric Symptoms in Alzheimer’s Disease: Focus on Agitation and Aggression. A Report from the EU/US/CTAD Task Force. J Prev Alzheimers Dis. 2015;2(3):184–8. doi: 10.14283/jpad.2015.77. PubMed PMID: 26413494; PubMed Central PMCID: PMCPMC4580980.PubMedGoogle Scholar
  11. 11.
    Lyketsos CG, Breitner JC, Rabins PV. An evidence-based proposal for the classification of neuropsychiatric disturbance in Alzheimer’s disease. Int J Geriatr Psychiatry. 2001;16(11):1037–42. PubMed PMID: 11746649.CrossRefPubMedGoogle Scholar
  12. 12.
    Canevelli M, Adali N, Voisin T, Soto ME, Bruno G, Cesari M, et al. Behavioral and psychological subsyndromes in Alzheimer’s disease using the Neuropsychiatric Inventory. Int J Geriatr Psychiatry. 2013;28(8):795–803. doi: 10.1002/gps.3904. PubMed PMID: 23147419.CrossRefPubMedGoogle Scholar
  13. 13.
    Lanctot KL, Amatniek J, Ancoli-Israel S, Arnold SE, Ballard C, Cohen-Mansfield J, et al. Neuropsychiatric signs and symptoms of Alzheimer’s disease: New treatment paradigms. Alzheimers Dement (N Y). 2017;3(3):440–9. doi: 10.1016/j.trci.2017.07.001. PubMed PMID: 29067350; PubMed Central PMCID: PMCPMC5651439.PubMedCentralGoogle Scholar
  14. 14.
    Kales HC, Gitlin LN, Lyketsos CG, Detroit Expert Panel on A, Management of Neuropsychiatric Symptoms of D. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762–9. doi: 10.1111/jgs.12730. PubMed PMID: 24635665; PubMed Central PMCID: PMCPMC4146407.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Rosenberg PB, Nowrangi MA, Lyketsos CG. Neuropsychiatric symptoms in Alzheimer’s disease: What might be associated brain circuits? Mol Aspects Med. 2015;43-44:25–37. doi: 10.1016/j.mam.2015.05.005. PubMed PMID: 26049034; PubMed Central PMCID: PMCPMC4600424.CrossRefPubMedGoogle Scholar
  16. 16.
    Lyketsos CG, Sheppard JM, Steinberg M, Tschanz JA, Norton MC, Steffens DC, et al. Neuropsychiatric disturbance in Alzheimer’s disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry. 2001;16(11):1043–53. PubMed PMID: 11746650.CrossRefPubMedGoogle Scholar
  17. 17.
    Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682–91. doi: 10.1001/jama.2014.93. PubMed PMID: 24549548; PubMed Central PMCID: PMCPMC4086818.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Charu V, Rosenberg PB, Schneider LS, Drye LT, Rein L, Shade D, et al. Characterizing Highly Benefited Patients in Randomized Clinical Trials. Int J Biostat. 2017;13(1). doi: 10.1515/ijb-2016-0045. PubMed PMID: 28541924.Google Scholar
  19. 19.
    Ho T, Pollock BG, Mulsant BH, Schantz O, Devanand DP, Mintzer JE, et al. Rand S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. Br J Clin Pharmacol. 2016;82(3):784–92. doi: 10.1111/bcp.12997. PubMed PMID: 27145364.CrossRefPubMedGoogle Scholar
  20. 20.
    Schneider LS, Frangakis C, Drye LT, Devanand DP, Marano CM, Mintzer J, et al. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer’s Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. Am J Psychiatry. 2016;173(5):465–72. doi: 10.1176/appi. ajp.2015.15050648. PubMed PMID: 26771737.CrossRefPubMedGoogle Scholar
  21. 21.
    Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–14. PubMed PMID: 7991117.CrossRefPubMedGoogle Scholar
  22. 22.
    de Medeiros K, Robert P, Gauthier S, Stella F, Politis A, Leoutsakos J, et al. The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. Int Psychogeriatr. 2010;22(6):984–94. doi: 10.1017/S1041610210000876. PubMed PMID: 20594384; PubMed Central PMCID: PMCPMC3314709.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry. 1987;48 Suppl:9–15. PubMed PMID: 3553166.PubMedGoogle Scholar
  24. 24.
    Cohen-Mansfield J. Conceptualization of agitation: results based on the Cohen-Mansfield Agitation Inventory and the Agitation Behavior Mapping Instrument. Int Psychogeriatr. 1996;8 Suppl 3:309–15; discussion 51-4. PubMed PMID: 9154580.PubMedGoogle Scholar
  25. 25.
    Rosenberg PB, Mielke MM, Lyketsos CG. Caregiver assessment of patients’ depression in Alzheimer disease: longitudinal analysis in a drug treatment study. Am J Geriatr Psychiatry. 2005;13(9):822–6. doi: 10.1176/appi. ajgp.13.9.822. PubMed PMID: 16166413.CrossRefPubMedGoogle Scholar
  26. 26.
    Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, et al. Validity and reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S22–32. PubMed PMID: 9236949.CrossRefPubMedGoogle Scholar
  27. 27.
    Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebocontrolled trials. Am J Geriatr Psychiatry. 2006;14(3):191–210. doi: 10.1097/01. JGP.0000200589.01396.6d. PubMed PMID: 16505124.CrossRefPubMedGoogle Scholar
  28. 28.
    Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165(7):844–54. doi: 10.1176/appi.ajp.2008.07111779. PubMed PMID: 18519523; PubMed Central PMCID: PMCPMC2714365.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Cohen-Mansfield J. Assessment of disruptive behavior/agitation in the elderly: function, methods, and difficulties. J Geriatr Psychiatry Neurol. 1995;8(1):52–60. PubMed PMID: 7710649.PubMedGoogle Scholar
  30. 30.
    Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol. 1989;44(3):M77–84. PubMed PMID: 2715584.CrossRefPubMedGoogle Scholar
  31. 31.
    Rabinowitz J, Davidson M, De Deyn PP, Katz I, Brodaty H, Cohen-Mansfield J. Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance. Am J Geriatr Psychiatry. 2005;13(11):991–8. doi: 10.1176/appi.ajgp.13.11.991. PubMed PMID: 16286443.CrossRefPubMedGoogle Scholar
  32. 32.
    Hendrix S, Brown BL, Cummings JL, Lyketsos C, Porsteinsson AP, Rosenberg PB, et al. Optimizing measurement of agitation and aggression in dementia. Alzheimer’s & Dementia. 2017;13(7 supplement):P264.CrossRefGoogle Scholar
  33. 33.
    Rabinowitz J, Katz I, De Deyn PP, Greenspan A, Brodaty H. Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer’s disease using risperidone. Int Psychogeriatr. 2007;19(2):227–40. doi: 10.1017/S1041610206003942. PubMed PMID: 16879763.CrossRefPubMedGoogle Scholar

Copyright information

© Serdi and Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Mary Sano
    • 1
    Email author
  • M. Soto
    • 2
  • M. Carrillo
    • 3
  • J. Cummings
    • 4
  • S. Hendrix
    • 5
  • J. Mintzer
    • 6
  • A. Porsteinsson
    • 7
  • P. Rosenberg
    • 8
  • L. Schneider
    • 9
  • J. Touchon
    • 10
    • 11
  • P. Aisen
    • 12
  • B. Vellas
    • 2
  • C. Lyketsos
    • 8
  • EU/US/CTAD Task Force members
  1. 1.Mount Sinai School of MedicineBronxUSA
  2. 2.Gerontopole, INSERM U1027, Alzheimer’s Disease Research and Clinical CenterToulouse University HospitalToulouseFrance
  3. 3.Alzheimer’s AssociationChicagoUSA
  4. 4.Cleveland Clinic Lou Ruvo Center for Brain HealthLas VegasUSA
  5. 5.Pentara CorporationSalt Lake CityUSA
  6. 6.Roper St. Francis CBRTCharlestonUSA
  7. 7.University of Rochester School of Medicine and DentistryRochesterUSA
  8. 8.Johns Hopkins University School of MedicineBaltimoreUSA
  9. 9.University of Southern CaliforniaLos AngelesUSA
  10. 10.University Hospital of MontpellierMontepellier Cedex 5France
  11. 11.INSERM 1061MontepellierFrance
  12. 12.Alzheimer’s Therapeutic Research Institute (ATRI), Keck School of MedicineUniversity of Southern CaliforniaSan DiegoUSA

Personalised recommendations